

R3 Stem Cell Publishes Research Paper on Safety of Intravenous Mesenchymal Stem Cell Therapy

SCOTTSDALE, AZ, UNITED STATES, May 30, 2025 /EINPresswire.com/ -- R3 Stem Cell, the global leader in regenerative therapies, recently published a research paper titled, "Safety of intravenous mesenchymal stem cell therapy: a meta-analysis of randomized controlled trials". The paper was published in the peer reviewed journal, Regenerative Medicine Reports, in its September 2025 publication. The article can be viewed here: <http://bit.ly/3T4VeC9>



When mesenchymal stem cells (MSCs) are administered intravenously, previous research has shown they have the ability to migrate to sites of inflammation and secrete bioactive molecules, making them potentially valuable in the treatment of proinflammatory conditions. This was the first study looking at the safety and efficacy of mesenchymal stem cell injection by intravenous method.

“

The overall safety of MSCs administered with IV infusion demonstrated in our analysis is not only impressive, but reinforces our approach to patient care!”

David Greene, MD, PhD, MBA

The paper looked at all treatment-related adverse events (AEs) in randomized control trials concerning MSC administration intravenously, and explored the safety of MSCs in clinical utilization. An impressive 36 research studies were included in the evaluation.

Adverse events evaluated were very broad across stem cell treatment for numerous disease categories including musculoskeletal, nervous system, GI, Immune system, renal, cardiac, hematologic, respiratory, skin, vascular, and liver as well.

The analysis indicated that mesenchymal stem cells are a safe option for patients, with some

papers showing a slightly elevated risk of adverse events such as infection or nervous system events. Otherwise, none of the adverse events reached statistical significance at all. According to R3 Stem Cell CEO David Greene, MD, PhD, MBA, "In over 26,000 stem cell procedures in the past 10 years, we've never seen a deep infection or nervous system side effects. The overall safety demonstrated in our analysis is not only impressive, but reinforces our approach to patient care!"

While short-term findings suggest that MSCs may be an effective treatment, further research is needed to evaluate their long-term effects. In the 36 studies reviewed, no significant adverse reactions or hypoglycemic events were observed in participants who received MSC treatment. This supports the view that MSC transplantation can be considered a safe therapeutic option for a range of diseases.

Added Dr. Greene, "We have the busiest [stem cell clinics in Mexico](#), with locations in Cancun, Tijuana and a beautiful new [stem cell clinic in Puerto Vallarta](#). IV [stem cell therapy for autism](#), anti-aging, kidney failure, autoimmune disorders, COPD, Lyme, and many other conditions has been very effective and safe as well."

R3 Stem Cell offers regenerative therapies at over 70 Centers in 7 countries including Mexico, India, Turkey, Philippines, Pakistan, South Africa and USA. Free consultations are offered simply by contacting R3 either at info@r3stemcell.com or by calling +1 (844) GET-STEM.

David Greene, MD, PhD, MBA

The image shows a screenshot of a journal article from 'Regenerative Medicine Reports' and a corporate award badge. The journal article is titled 'Safety of intravenous mesenchymal stem cell therapy: a meta-analysis of randomized controlled trials' and lists authors including Habiba, Umm E, Greene, David Lawrence, Ahmad, Khalil, Shamim, Sabiha, Khan, Nasar, Umer, and Amna. The article is published in 'Regenerative Medicine Reports 2(3):p 83-99, September 2025'. Below the article is a badge from 'The Enterprise World' titled 'The Most Trusted REGENERATIVE MEDICINE Companies - 2025'. The badge features the 'Corporate Vision Corporate Excellence Awards' logo and identifies 'R3 Stem Cell' as a 'Leading Innovators in Regenerative Cell Therapy - USA' for the year '-2025-'.

Log in or Register Get new issue alerts Submit a Manuscript

Regenerative Medicine Reports

Home Current Issue Previous Issues For Authors Published Ahead-of-Print Journal Info

RESEARCH ARTICLE

Safety of intravenous mesenchymal stem cell therapy: a meta-analysis of randomized controlled trials

Habiba, Umm E^{1,2,3,*}; Greene, David Lawrence^{1,2,3,4}; Ahmad, Khalil⁵; Shamim, Sabiha^{1,2,3}; Khan, Nasar^{1,2,3,4}; Umer, Amna^{1,2,3}

Author Information

Regenerative Medicine Reports 2(3):p 83-99, September 2025. | DOI: 10.4103/REGENMED.REGENMED-D-25-00006

Outline Images Download Cite

OPEN

The Enterprise World

The Most Trusted

REGENERATIVE MEDICINE

★★★★★ Companies - 2025

Corporate Vision Corporate Excellence Awards

R3 Stem Cell

Leading Innovators in Regenerative Cell Therapy - USA

-2025-

R3 Stem Cell International

+1 (888) 988-0515

[email us here](#)

Visit us on social media:

[Instagram](#)

[YouTube](#)

[TikTok](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/817356387>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.